Home Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: I. Analyte definition and proposal of a candidate reference method
Article
Licensed
Unlicensed Requires Authentication

Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: I. Analyte definition and proposal of a candidate reference method

  • International Federation of Clinical Chemistry and Laboratory Medicine (IFCC): Working Group on Standardization of Carbohydrate-deficient Transferrin (IFCC-WG-CDT): Jan-Olof Jeppsson , Torsten Arndt , François Schellenberg , Jos P.M. Wielders , Raymond F. Anton , John B. Whitfield and Anders Helander
Published/Copyright: April 1, 2007
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 45 Issue 4

Abstract

An alcohol-associated change in the serum transferrin glycoform pattern, carbohydrate-deficient transferrin (CDT), is used as a biomarker of chronic moderate to heavy alcohol consumption. A current limitation in CDT analysis is the lack of standardization, which hampers clinical and analytical comparison between studies. This situation prompted initiation of a Working Group (WG) on CDT Standardization under the auspices of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). The standardization work aims to define and validate the analyte, select a reference method, work out procedures for the production of reference materials, and make suggestions for the clinical usage of CDT. The first recommendation of the WG is that disialotransferrin should be the primary target molecule for CDT measurement and the single analyte on which CDT standardization is based. It is further recommended that HPLC should be the analytical principle considered as the basis of an interim reference method until a suitable mass spectrometric reference method is established. In clinical use, CDT should be expressed in a relative amount (% CDT), to compensate for variations in the total transferrin concentration.

Clin Chem Lab Med 2007;45:558–62.


Corresponding author: Anders Helander, Chair, IFCC-WG-CDT, Alcohol Laboratory, L7:03, Karolinska University Hospital Solna, 171 76 Stockholm, Sweden Phone: +46-8-51771530, Fax: +46-8-51771532,

Received: 2006-12-19
Published Online: 2007-04-01
Published in Print: 2007-04-01

©2007 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Electrophoretic separations of cerebrospinal fluid proteins in clinical investigations
  2. Haemophilia A: molecular insights
  3. Quality specifications: self pleasure for clinical laboratories or added value for patient management?
  4. A724A polymorphism of sarco(endo)plasmic reticulum Ca2+-ATPase 2 (SERCA2) in hypertensive patients
  5. Associations of common polymorphisms in the thymidylate synthase, reduced folate carrier and 5-aminoimidazole-4-carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase genes with folate and homocysteine levels and venous thrombosis risk
  6. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 (PPARγ-2) gene is associated with greater insulin sensitivity and decreased risk of type 2 diabetes in an Iranian population
  7. A novel frameshift mutation of the lecithin:cholesterol acyltransferase (LCAT) gene associated with renal failure in familial LCAT deficiency
  8. The c.–292C>T promoter polymorphism increases reticulocyte-type 15-lipoxygenase-1 activity and could be atheroprotective
  9. The genetic polymorphisms of β3-adrenergic receptor (AR) Trp64Arg and β2-AR Gln27Glu are associated with obesity in Chinese male hypertensive patients
  10. Diagnostic performance of combined specific urinary proteins and urinary flow cytometry in urinary tract pathology
  11. Diagnostic accuracy of the FIDIS multiplex fluorescent microsphere immunodetection system for anti-extractable nuclear antigen (ENA) antibodies in connective tissue diseases
  12. Fluorimetric quantitation of citalopram and escitalopram in plasma: developing an express method to monitor compliance in clinical trials
  13. Free serum cortisol: quantification applying equilibrium dialysis or ultrafiltration and an automated immunoassay system
  14. Percutaneous coronary intervention-induced variations in systemic parameters of inflammation: relationship with the mode of stenting
  15. Multicentre physiological reference values for the concentration of creatininium in plasma and diagnostic specificity of glomerular filtration rate estimated with the MDRD equation
  16. Serum levels of ischemia-modified albumin in healthy volunteers after exercise-induced calf-muscle ischemia
  17. Reference intervals for follicle-stimulating hormone, luteinizing hormone and prolactin in children and young adults on the bioMérieux Mini-Vidas system
  18. Limits of usual biochemical alcohol markers in cord blood at term: a fetal/maternal population-based study
  19. Implementing the Stockholm Conference hierarchy of objective quality criteria in a routine laboratory
  20. The diffusion of innovations theory could help laboratorians in research translation
  21. Detection of CYP2D6 polymorphisms *9, *10, and *41 using ARMS-PCR and their allelic frequencies in 400 psychiatric patients
  22. Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: I. Analyte definition and proposal of a candidate reference method
  23. Measurement of free thyroxine in laboratory medicine – proposal of measurand definition
Downloaded on 13.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2007.107/html
Scroll to top button